Faeth Therapeutics (FTH) Cash & Equivalents (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Cash & Equivalents came in at $152.3 million in Q1 2026, up 1442.22% YoY from $9.9 million in Q1 2025, and up 1657.33% on a QoQ basis from $8.7 million in Q4 2025.
Faeth Therapeutics (FTH) Cash & Equivalents (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Cash & Equivalents data on file, last reported at $152.3 million in Q1 2026.
- Quarterly Cash & Equivalents rose 1442.22% year-over-year to $152.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $152.3 million (up 1442.22% YoY) and the FY2025 annual result came in at $8.7 million, down 13.27% from the prior year.
- Cash & Equivalents grew to $152.3 million in Q1 2026, from $8.7 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $152.3 million in Q1 2026 to a low of $8.1 million in Q1 2023.
- A 5-year average of $19.8 million and a median of $11.0 million in 2024 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 94.85% — and 2026, when it surged 1442.22%.
- Tracing FTH's Cash & Equivalents over 5 years: stood at $17.8 million in 2022, then retreated by 26.88% to $13.0 million in 2023, then dropped by 23.19% to $10.0 million in 2024, then fell by 13.27% to $8.7 million in 2025, then soared by 1657.33% to $152.3 million in 2026.
- The last three Cash & Equivalents figures came in at $152.3 million (Q1 2026), $8.7 million (Q4 2025), and $10.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Faeth Therapeutics | 179.31 Mn | 179.31 Mn | - | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.90 Mn |
| Mar 31, 2026 | 152.33 Mn |
| Dec 31, 2025 | 8.67 Mn |
| Sep 30, 2025 | 10.56 Mn |
| Jun 30, 2025 | 12.56 Mn |
| Mar 31, 2025 | 9.88 Mn |
| Dec 31, 2024 | 9.99 Mn |
| Sep 30, 2024 | 19.13 Mn |
| Jun 30, 2024 | 11.89 Mn |
| Mar 31, 2024 | 10.96 Mn |
| Dec 31, 2023 | 13.01 Mn |
| Sep 30, 2023 | 11.34 Mn |
| Jun 30, 2023 | 10.23 Mn |
| Mar 31, 2023 | 8.11 Mn |
| Dec 31, 2022 | 17.80 Mn |
| Sep 30, 2022 | 11.45 Mn |
| Jun 30, 2022 | 9.90 Mn |
| Mar 31, 2022 | 8.72 Mn |
| Dec 31, 2021 | 7.16 Mn |
| Sep 30, 2021 | 9.53 Mn |